Norbrook has announced the launch of Moxiclear, a monthly spot-on broad spectrum endectocide for the treatment and prevention of parasites in dogs, cats and ferrets.

Moxiclear contains moxidectin and imidacloprid.

In dogs, Moxiclear can be used for the treatment and prevention of flea infestations and as part of a treatment plan for flea allergic dermatitis. It is also indicated for lungworm, ear mites, sarcoptes mites, biting lice, round worm, hookworm, whipworm, skinworm, and prevents heartworm.

In cats, Moxiclear can be used for the treatment and prevention of flea infestation and flea allergic dermatitis, as well as ear mite infestations. It is also indicated for notoedric mange, gastrointestinal nematodes; whipworm, roundworm and hookworm, and for the prevention of heartworm disease.

In ferrets, Moxiclear can be used to treat and prevent flea infestation, and prevent heartworm.

Moxiclear is available for 4kg-40kg dogs, with four pipette fill sizes. Small cats and ferrets weighing less than 4kg are catered for with a 0.4ml pipette. Large cats weighing 4-8kg can be treated with the Moxiclear 0.8ml pipette.  

Lorron Bright, Norbrook Product Manager, said: "Moxiclear offers good value, broad-spectrum parasite control for dogs, cats and ferrets. This latest launch provides our customers with an excellent value, alternative choice for a imidacloprid/moxidectin product."

Richard Palmer, Norbrook Global Head of Sales and Marketing, said: "Moxiclear spot-on is the 11th product we have launched in the past three years. Six of the new products are in the companion animal sector as we continue to strengthen our foothold in the growing global companion animal market. Norbrook is committed to delivering a strong new product pipeline, along with our multi-year £50 million investment programme."